Twists and turns to translating 4-1BB cancer immunotherapy.
Miguel F SanmamedIñaki EtxeberríaItziar OtanoIgnacio MeleroPublished in: Science translational medicine (2020)
Previous shortcomings of CD137-targeted immunotherapy may be overcome by engineered bispecific agents (Claus et al, this issue).